Xbiotech Inc. (XBIT) — SEC Filings
Xbiotech Inc. (XBIT) — 23 SEC filings. Latest: 8-K (Dec 9, 2025). Includes 9 8-K, 6 10-Q, 3 10-K/A.
View Xbiotech Inc. on SEC EDGAR
Overview
Xbiotech Inc. (XBIT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 9, 2025: XBiotech Inc. announced on December 5, 2025, the departure of Director Dr. George J. V. Johnson and the election of new Director Dr. David M. R. Johnson. The company also reported on compensatory arrangements for certain officers. The filing was made on December 9, 2025.
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 1 bearish, 19 neutral, 3 mixed. The dominant filing sentiment for Xbiotech Inc. is neutral.
Filing Type Overview
Xbiotech Inc. (XBIT) has filed 9 8-K, 6 10-Q, 1 8-K/A, 1 DEF 14A, 3 10-K/A, 2 10-K, 1 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of XBIT's 21 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not Disclosed |
| Net Income | -$18.648M |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | $147.367M |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. George J. V. Johnson
- Dr. David M. R. Johnson
Industry Context
XBiotech operates in the highly competitive biopharmaceutical sector, focusing on the development of novel therapies for oncology, rheumatology, and neurology. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and the ability to navigate complex market dynamics and competitive landscapes.
Top Tags
corporate-governance (5) · Pharmaceuticals (4) · 10-Q (4) · XBiotech (4) · amendment (3) · management-change (3) · pharmaceuticals (3) · governance (2) · Biotechnology (2) · IL-1a (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $147.367M | Decreased from $172.677M at Dec 31, 2024, indicating significant cash burn. |
| Net Loss (9 months) | $18.648M | Improved from $28.023M in prior year, but still a substantial loss. |
| Net Loss (3 months) | $6.008M | Increased from $5.015M in Q3 2024, showing a worsening quarterly loss. |
| R&D Expenses (9 months) | $22.032M | Decreased from $29.936M in prior year, reflecting cost management or reduced trial activity. |
| Convertible Loans Repaid | $10.250M | Reduced total current liabilities from $15.105M to $3.565M, improving balance sheet. |
| Shares Outstanding | 30,487,731 | Consistent at September 30, 2025, indicating no recent dilution from new equity issuance. |
| Net Loss (Q2 2025) | $1.756M | Decreased significantly from $13.006M in Q2 2024, representing an 86.5% reduction. |
| Net Loss (YTD Q2 2025) | $12.640M | Reduced from $23.008M in YTD Q2 2024, a 45.1% improvement. |
| Research and Development Expenses (Q2 2025) | $5.336M | Down from $12.984M in Q2 2024, a 59% decrease. |
| Research and Development Expenses (YTD Q2 2025) | $16.954M | Reduced from $22.809M in YTD Q2 2024, a 25.7% decrease. |
| Net Cash Used in Financing Activities | $10.250M | Primarily due to the repayment of a $10 million related-party convertible loan. |
| Janssen Transaction Cash Payment | $750M | Received in 2019 for a True Human antibody, providing significant historical capital. |
| Director Nominees | 5 | Number of directors proposed for election at the 2025 Annual Meeting. |
| Fiscal Year | 2025 | Year for which Whitley Penn LLP is proposed as the independent auditor. |
| Meeting Date | August 29, 2025 | Date of XBiotech's Annual Meeting of Shareholders. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Xbiotech Inc. (XBIT)?
Xbiotech Inc. has 23 recent SEC filings from Jan 2024 to Dec 2025, including 9 8-K, 6 10-Q, 3 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XBIT filings?
Across 23 filings, the sentiment breakdown is: 1 bearish, 19 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Xbiotech Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xbiotech Inc. (XBIT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xbiotech Inc.?
Key financial highlights from Xbiotech Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XBIT?
The investment thesis for XBIT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xbiotech Inc.?
Key executives identified across Xbiotech Inc.'s filings include Dr. George J. V. Johnson, Dr. David M. R. Johnson.
What are the main risk factors for Xbiotech Inc. stock?
Of XBIT's 21 assessed filings, 1 were flagged high-risk, 15 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Xbiotech Inc.?
Forward guidance and predictions for Xbiotech Inc. are extracted from SEC filings as they are enriched.